DESIGN AND DEVELOPMENT OF ORODISPERSIBLE TABLETS USING NOVEL SUPERDISINTEGRANTS
Main Article Content
Keywords
Tadalafil, Indion 234, Indion 234s, Direct compression method
Abstract
The present work aimed at preparing oro-dispersible tablets of Tadalafil with the purpose of developing a dosage form for a very quick onset of action, which is very convenient for administration, without the problem of swallowing and using water. The tablets of tadalafil was prepared by using superdisintegrants like sodium starch glycolate, Indion 234s, Indion 234 as an ion exchange resins by direct compression method. The formulated fast dissolving tablets were evaluated for physical characteristics such as Hardness, thickness, uniformity of weight, drug content uniformity, Invitro disintegration and invitro dissolution .The formulations were subjected to disintegration, In-vitro drug release tests. The FTIR and DSC studies revealed that no physicochemical interaction between excipients and drug. Fast dissolving tablets of tadalafil containing combination of SSG and Indion 234s as superdisintegrant showed (94.33%) drug release within 10min. Percentage content uniformity (99.20%). Fast dissolving tablets of Tadalafil can be considered suitable for clinical use in the treatment of Erectile Dysfunctioning.
References
2. Bharat V. Jain, Rupali R. Patil, Sonali S. Wankhede, Dipak R.Patil, Dr.Shashikant D. Barhate; Development of Mouth Dissolving Tablets of Grenisetron Hydrochloride using three different techniques; International Journal of Pharmaceutical Research and Development; 2011; Vol.3(3),May. 2011(23-26).
3. Kumara Swamy S., Narendra D. and Agaiah Goud B; Formulation and Evaluation of Orodispersible Tablet of Theophylline using different super disintegtants; Journal of Advance Pharmaceutical Sciences; Vol.2 , 2012: 260-264.
4. Drug Bank / Drug Data: online.
5. K. Mallikarjuna Rao, V. Sreenivasulu, M. Gobinath, C. Thejaswi,J.Radha Rani; Formulation and invitro characterization of orodispersible tablets of Tadalafil by using Dry Granulation Method with Superdisintegrants; Journal of research and development; June 2012/ Vol.1(2): 36-
6. Bharat Jain, Shashikant Barhate; Indion 234s as a disintegrant: Formulation and Evaluation of Grenisetron Hydrochloride Orodispersible Tablets; Iventy Impact :Novel Excipients ; Vol. 2013, issue 2, 81-83.
7. Indion 234s Description : Ion Exchange India Limited. www.ion india.com
8. Indion 234 Description : Ion Exchange India Limited. www.ion india.com
9. C. V. S Subrahmanyam “Text Book of Physical Pharmacy”, 2nd edition , Delhi: Vallabh Prakashan, 2004, 210-228.
10. Aulton M E. Eds: Pharmaceutics: The science of dosage form and design, 2nd ed., Churchill Livingstone, USA , 1998, pp.223-253.
11. Martin A, Swarbrick J, Cammarata A, “Physical Pharmacy”, 3rd edition, Verghese publishing company Bombay, 1991, pp. 492-520.
12. Hareesha Chamarthi, Ramesh Kannuri, Senthil Kumar M., Gargeyi pavuluri, Swathi Krishna. K. V.; Formulation and evaluation of orodispersible tablet of Escitalopram Oxalte by superdisintegrants addition method; International Journal of Pharmaceutical Research and Development; 2011; Vol 3(8): November 2011 (65-72).
13. Mahajan Yogesh Y, Tekade Bharat W., Thakre Vinod M., Patil Vijay R., Jagdale Sunil; Formulation and Evaluation of Orally Disintegrating Tablet of Ondensetron Hydrochloride; International Journal of Drug Delivery 4 (2012): 09-19.
14. The Indian Pharmacopoeia.(2010). Govt of India, Ministry of Family Welfare, the Indian Pharmacopoeial commission, Gaziabad page 1815-1817.
15. Lachman L, Lieberman HA, Kanig J L. The theory and practice of industrial pharmacy, 3rd edn, Varghese publishing house, Bombay, 1986, pp. 297-300.
16. Suryakant B. Jadhav, Dinesh M. Sakarkar, Datta R. Kaudewar, Girish S. Kaminwar, and Rajesh V. Kshirsagar; Formulation and Evaluation of Mouth Dissolving Tablets of Diltiazem Hydrochloride; Pelgia research library : Der Pharmacia Sinica; 2011, 2(6): 23- 31.
17. K.B.Deshpande; Orodispersible Tablet: An Overview of Formulation and Technology ; International Journal of Pharma and Biosciences, 2(1) : 2011; 0975-6299.